Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate <scp>T</scp> cells by inducing degradation of <scp>T</scp> cell repressors <scp>I</scp> karos and <scp>A</scp> iolos via modulation of the <scp>E</scp> 3 ubiquitin ligase complex <scp>CRL</scp> 4 <scp> <sup>CRBN</sup> </scp>
Anita K. Gandhi(Bristol-Myers Squibb (United States)), Rajesh Chopra(Vardhman Mahavir Medical College & Safdarjung Hospital)
Cited by 619
Related Papers
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
|Blood|2006|843
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
|Blood|2000|502
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
|Blood|2015|200